Barclays PLC Nektar Therapeutics Put Options Transaction History

Barclays PLC

12 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2020 Aug 12, 2020	SELL	$16.86 - $23.44 $2.06 Million - $2.87 Million	-122,400 Reduced 80.53%	29,600 $686,000
Q1 2020 May 13, 2020	BUY	$14.47 - $27.96 $60,774 - $117,432	4,200 Added 2.84%	152,000 $2.71 Million
Q4 2019 Feb 10, 2020	BUY	$15.87 - $23.12 $1.33 Million - $1.94 Million	83,900 Added 131.3%	147,800 $3.19 Million
Q3 2019 Nov 14, 2019	SELL	$16.91 - $36.27 $366,947 - $787,059	-21,700 Reduced 25.35%	63,900 $1.16 Million
Q2 2019 Aug 14, 2019	BUY	$31.0 - $36.3 $1.19 Million - $1.4 Million	38,500 Added 81.74%	85,600 $3.05 Million
Q1 2019 May 15, 2019	BUY	$31.58 - $46.35 $394,750 - $579,375	12,500 Added 36.13%	47,100 $1.58 Million
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $3.5 Million - $6.51 Million	-114,900 Reduced 76.86%	34,600 $1.14 Million
Q3 2018 Nov 14, 2018	BUY	$46.46 - $68.49 $2.33 Million - $3.44 Million	50,200 Added 50.55%	149,500 $9.11 Million
Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $4.28 Million - $9.66 Million	92,500 Added 1360.29%	99,300 $4.85 Million
Q1 2018 May 15, 2018	SELL	$57.4 - $108.44 $1.29 Million - $2.43 Million	-22,400 Reduced 76.71%	6,800 $723,000
Q4 2017 Feb 14, 2018	BUY	$23.02 - $60.5 $98,986 - $260,150	4,300 Added 17.27%	29,200 $1.74 Million
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $442,971 - $597,600	24,900	24,900 $598,000

147

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $201M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.